

Cannabinoid receptor deficiencies drive immune response dynamics in *Salmonella* infection

Hailey A. Barker¹, Saloni Bhimani¹, Deyaneira Tirado¹, Leandro Nascimento Lemos², Luiz F.W. Roesch¹, Mariola J. Ferraro^{1,*}

¹ Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, Florida, USA

²Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, São Paulo, Brazil

* Mariola J. Ferraro, Microbiology and Cell Science Department, University of Florida, Gainesville, FL 32611

Email: mjerraro@ufl.edu

Author ORCIDs:

SB: 0000-0001-6358-5235
HAB: 0000-0002-3420-8059
LNL: 0000-0002-0898-568X
LFWR: 0000-0003-1450-8828
MJF: 0000-0003-0459-7716

Author Contributions: H.B.: Investigation; Data Curation; Writing – Review & Editing; S.B.: Investigation; Formal Analysis; D.T.: Investigation; Data Curation; Writing – Review & Editing; L.N.L.: Formal Analysis; Data Curation; Visualization; L.F.W.R.: Formal Analysis; Data Curation; Visualization; Writing – Original Draft. M.J.F.: Conceptualization; Methodology; Supervision; Writing – Original Draft; Writing – Review & Editing.

Competing Interest Statement: The authors declare no competing financial or non-financial interests related to this work.

Abstract

This study investigated the roles of cannabinoid receptors 1 and 2 (CB1R and CB2R) in regulating host responses to *Salmonella Typhimurium* in C57BL/6 mice. The absence of both receptors significantly impaired host resilience, as evidenced by increased weight loss, deteriorated body condition, and reduced survival following infection. Notably, CB1R deficiency resulted in more pronounced weight loss and heightened susceptibility to bacterial proliferation, as demonstrated by increased *Salmonella* dissemination to organs. In addition, both CB1R and CB2R knockout mice exhibited alterations in immune cell recruitment and cytokine production. CB1R-KO mice displayed increased T cell and macrophage populations, whereas CB2R-KO mice showed a reduction in NK cells, indicating receptor-specific effects on immune cell mobilization. Cytokine profiling of macrophages post-infection revealed that CB1R-KO mice had reduced IL-10 levels, along with increased IL-6 and TGF- β , suggesting a dysregulated polarization state that combines pro-inflammatory and regulatory elements. In contrast, CB2R-KO mice exhibited a profile consistent with a more straightforward pro-inflammatory shift. Furthermore, microbiota analysis demonstrated that CB2R-KO mice experienced significant gut dysbiosis, including reduced levels of beneficial *Lactobacillus* and *Bifidobacterium* species and an increase in pro-inflammatory *Alistipes* species post-infection. Functional microbiome analysis further indicated declines in key metabolic pathways, such as the *Bifidobacterium* shunt, L-glutamine biosynthesis, and L-lysine biosynthesis, suggesting microbiota-driven immune

dysregulation. Together, these findings highlight the distinct, non-redundant roles of CB1R and CB2R in modulating innate immunity, host defense, and microbiota composition during bacterial infections.

Keywords: Cannabinoid receptors; Macrophage polarization; *Salmonella* infection; Immune response; Host-pathogen interactions

Significance Statement

Understanding the role of cannabinoid receptors in immune regulation is important for identifying new therapeutic targets for bacterial infections. Our study demonstrates that CB1R and CB2R play distinct, non-redundant roles in host defense against *Salmonella* Typhimurium. The absence of these receptors impairs host resilience, increases bacterial dissemination, and alters immune cell recruitment and cytokine production. Notably, CB1R deficiency leads to enhanced weight loss, increased bacterial spread, and a dysregulated macrophage cytokine profile—characterized by reduced IL-10 and elevated IL-6 and TGF- β —while CB2R deficiency is associated with reduced NK cell numbers and a more pronounced pro-inflammatory cytokine profile. These findings reveal a receptor-specific balance in immune responses, suggesting that cannabinoid signaling modulates infection outcomes. Targeting CB1R and CB2R pathways may offer novel strategies to enhance host immunity and improve treatments for bacterial infections in the future.

Main Text

Introduction

Cannabis consumption is increasing in the U.S. for both recreational and medical purposes¹, yet its effects on infections remain inadequately understood. Cannabis contains over 113 cannabinoids (CBs), including Delta-9-tetrahydrocannabinol (THC), a partial agonist of the cannabinoid type 1 receptor (CB1R) primarily in the central nervous system, and CB2R, which is abundant in immune cells². These medically relevant cannabinoids include Cannabidiol (CBD), Nabiximol or Dronabinol. CBs interact with the endocannabinoid system (ECS), a neuromodulatory network comprising CB receptors, their ligands, endocannabinoids (eCBs), and the enzymes responsible for eCB synthesis and breakdown. The ECS functions through the binding of eCBs/CBs to CB1R and CB2R receptors³. Endogenous eCBs, including anandamide (AEA)⁴ and 2-arachidonoylglycerol (2-AG)^{5,6}, are bioactive lipids derived from polyunsaturated fatty acids. Interestingly, the ECS has been shown to influence macrophage polarization. Activation of CB2R predominantly promotes anti-inflammatory M2 macrophage polarization⁷⁻¹², while the roles of CB1R in macrophage polarization remain almost completely underexplored. The underappreciation of CB1R's role in immune regulation highlights the importance of further exploring its involvement. Given the diverse cellular pathways influenced by the ECS, its involvement in the host response to bacterial infections is a topic of interest. Recent review has highlighted the complexity of ECS's role in this context¹³. Unfortunately, the assessment of CBs' effects on bacterial infections has been confined to a very limited number of studies¹⁴⁻²⁵, yielding heterogeneous outcomes contingent on the infection model used. Some infection models show improved outcomes with CB treatment²⁰, while others demonstrate immunosuppressive effects, leading to decreased host resistance^{19,23,24}. These variable outcomes emphasize the need for further and context-dependent research.

Salmonella presents a unique challenge due to its intricate survival strategies within the host. Our previous studies described *Salmonella*'s influence on host lipid metabolism, including eicosanoids²⁶⁻²⁸, which serve as sources of eCBs. We have shown that *Salmonella* infection reduces the activity of α/β -hydrolase domain 6 (ABHD6) and fatty acid amide hydrolase (FAAH), two key enzymes responsible for 2-arachidonoylglycerol (2-AG) degradation in macrophages²⁹. While 2-AG has been shown to enhance the phagocytosis of zymosan particles, its role in *Salmonella* phagocytosis and intracellular survival remains unknown²⁹. Further supporting a potential antimicrobial function, elevated 2-AG levels in a murine model were shown to protect

against gastrointestinal infections caused by *Citrobacter rodentium*²⁵, suggesting a direct role for 2-AG in countering bacterial virulence. However, the specific contributions of cannabinoid receptors to host immune responses against *Salmonella* infection remain largely unknown, necessitating further study.

In this study, we examined the roles of CB1R and CB2R signaling in modulating the host response to *Salmonella* infection, aiming to uncover novel, cannabinoid receptor-mediated mechanisms of innate immune regulation. Our findings highlight a role for the endocannabinoid system not only in shaping the gut microbiome but also in orchestrating host innate immune defenses against bacterial pathogens.

Results

Analysis of endocannabinoid pathway modulation in *Salmonella*-infected macrophages

Building on our previous observation that endocannabinoid hydrolases, including FAAH and ABHD6, were downregulated at 18- and 24-hours post-infection (hpi) in macrophages infected with *Salmonella*²⁷, we investigated whether the expression of endocannabinoid receptor genes, *cnr1* and *cnr2* (encoding CB1R and CB2R proteins, respectively), followed a similar regulatory pattern. To assess this, we examined *Cnr1* and *Cnr2* expressions in bone marrow-derived macrophages (BMDMs) isolated from C57BL/6 mice and infected with *Salmonella* at a multiplicity of infection (MOI) of 30. Our results revealed a significant downregulation of *Cnr1* as early as 2 hpi, which persisted through 24 hpi (**Fig. S1A**), suggesting rapid suppression of CB1R signaling as part of an early immune response. In contrast, *Cnr2* expression remained stable across all time points, indicating a distinct regulatory mechanism for CB2R in *Salmonella*-infected BMDMs under these conditions (**Fig. S1B**). These findings highlight a potential role for CB1R in the host response to *Salmonella* infection, while CB2R may be regulated through post-transcriptional or post-translational mechanisms.

Cannabinoid receptors affect the recruitment of immune cells during infection.

Distinct expression patterns of *Cnr1* and *Cnr2* during *Salmonella* infection suggest that CB1R and CB2R play different roles in macrophage responses. To assess their functional impact, we examined immune cell recruitment in vivo using knockout (KO) mouse models. CB1R-KO, CB2R-KO, and wild-type (WT) C57BL/6 mice were orally infected with *Salmonella* (7.5×10^7 CFUs) and analyzed at 4 days post-infection (dpi). Flow cytometry revealed that CB2R-KO mice had a significant reduction in natural killer (NK) cells (**Fig. 1B**), while T cell (CD3⁺) and B cell populations remained unchanged (**Fig. 1C, D**). In contrast, CB1R-KO mice exhibited an increased percentage of T cells and a decreased percentage of B cells (**Fig. 1C, D**). Additionally, CB1b⁺F4/80⁺ macrophages were elevated in CB1R-KO mice but reduced in CB2R-KO mice (**Fig. 1E-G**), whereas neutrophils followed the opposite trend. These findings demonstrate distinct, receptor-specific roles for CB1R and CB2R in immune cell recruitment during *Salmonella* infection.

Macrophage cytokine production and polarization in CB1R and CB2R KO mice

Given the observed differences in immune cell recruitment, we next evaluated cytokine production and macrophage polarization in the spleens of *Salmonella*-infected mice (**Fig. 2**). Flow cytometry analysis revealed that splenic macrophages from CB1R knockout (KO) mice produced significantly less IL-10 (**Fig. 2A**) while simultaneously expressing higher levels of IL-6 (**Fig. 2B**) and TGF- β (**Fig. 2C**) compared to wild-type controls. In contrast, macrophages from CB2R-KO mice also showed reduced IL-10 production and elevated TGF- β levels (**Fig. 2C**), while their IL-6 levels remained unchanged. Notably, intracellular TNF- α levels were lower in CB1R-KO macrophages and higher in CB2R-KO macrophages (**Fig. 2D**); however, these measurements only reflect intracellular abundance rather than secreted cytokine levels. Furthermore, CB1R-KO macrophages exhibited increased expression of the costimulatory marker CD86 (**Fig. 2E**) without significant changes in CD206 expression. In contrast, CB2R-KO macrophages not only displayed

higher CD86 levels (**Fig. 2E**) but also demonstrated a decrease in CD206 expression (**Fig. 2F**), collectively indicating a shift toward a pro-inflammatory phenotype.

While both CB1R-KO and CB2R-KO macrophages show elements of a pro-inflammatory, M1-like polarization, a closer look reveals distinctions between the two (**Fig. 2G**). Specifically, CB2R deficiency results in a clear M1 profile with reduced IL-10, increased CD86, and decreased CD206. In contrast, CB1R deficiency leads to a more complex or dysregulated state: despite reduced IL-10 and increased CD86—features consistent with M1 polarization—the concomitant elevation of both IL-6 and TGF- β suggests elements of an M2b-like phenotype. This mixed profile may impair effective bacterial clearance despite the pro-inflammatory context.

Overall, the data suggest that CB1 and CB2 signaling help maintain a balanced, anti-inflammatory (M2) state, and that the loss of either receptor skews macrophages toward a pro-inflammatory phenotype. However, while CB2R deficiency produces a straightforward M1 shift, CB1R deficiency results in a dysregulated polarization that combines aspects of both M1 and M2b profiles.

Bacterial burden in cannabinoid receptor knockout mice and in vitro

To investigate the role of cannabinoid receptor signaling in host defense against *Salmonella* infection, we assessed bacterial burden in CB1R-KO, CB2R-KO, and WT mice using a sepsis model. Flow cytometry analysis revealed a significant increase in CD45⁺ *Salmonella*⁺ cells in the spleens of CB1R-KO mice (**Fig. 3A, B**) and in all splenocytes (**Fig. 3C**), which correlated with markedly higher bacterial loads in both the liver and spleen of CB1R-KO mice compared to WT controls (**Fig. 3C**). These findings indicate that CB1R deficiency promotes bacterial dissemination, leading to a more severe systemic infection. In contrast, CB2R-KO mice did not exhibit a significant difference in bacterial burden compared to WT controls, suggesting that CB1R plays a dominant role in controlling bacterial proliferation and organ dissemination in this model. These results highlight the critical function of CB1R in host defense against *Salmonella*, likely through its influence on immune cell activation and bacterial clearance mechanisms.

Next, to investigate how CB1R and CB2R deficiencies affect bacterial burden at the cellular level, we conducted in vitro infections using BMDMs isolated from CB1R-KO, CB2R-KO, and WT mice. Macrophages were infected with *Salmonella* for 2 or 24 hours, followed by quantification of bacterial presence and total cell counts. DAPI staining was used to determine cell numbers, while GFP fluorescence intensity, normalized to DAPI, was measured to assess bacterial association within macrophages. At 2 hpi, both CB1R-KO and CB2R-KO macrophages exhibited slightly lower bacterial association per cell compared to WT controls (**Fig. S2A**). However, by 24 hpi, this trend reversed in CB1R-KO macrophages, where intracellular bacteria increased compared to WT cells (**Fig. S2B, C**). This finding is consistent with the increased bacterial burden observed in CB1R-KO mice. Cytokine analysis at 6 hpi revealed some change in inflammatory responses. TNF- α levels were elevated in CB1R-KO macrophages but reduced in CB2R-KO cells, while IL-10 was decreased in both KO groups relative to WT controls (**Fig. S2D, E**).

All these findings suggest that CB1R is a regulator of macrophage-mediated bacterial control and systemic infection severity, pointing towards its putative role in host-pathogen interactions during *Salmonella* infection. A heightened pro-inflammatory phenotype may initially be beneficial for bacterial killing but can ultimately fail to control bacterial growth if not properly regulated, as appears to be the case in CB1R-KO macrophages.

Host resilience and survival in CB1R and CB2R deficient mice

To assess the impact of CB1R and CB2R deficiencies on host resilience during *Salmonella* infection, we conducted a *Salmonella* challenge study in CB1R-KO, CB2R-KO, and WT mice including outputs such as weight loss monitoring, body condition scoring, serum cytokine analysis, and survival tracking. Groups of mice were orally infected with *Salmonella* Typhimurium

(7.5×10^7 CFUs) and monitored for one-week post-infection. Body weight and condition scores were recorded daily, while serum cytokine levels were measured to assess inflammatory responses. Survival rates were tracked for up to four days post-infection to determine overall susceptibility. WT mice exhibited only a moderate decline in body weight and maintained relatively stable body condition scores throughout the infection period (**Fig. 4A, B**). In contrast, both CB1R-KO and CB2R-KO mice suffered significant weight loss and exhibited a notable decline in body condition, indicating increased susceptibility to infection-induced cachexia (**Fig. 4C, D**). Serum cytokine analysis revealed key differences in systemic inflammation. CB1R-KO mice displayed significantly elevated IL-1 β and TNF- α levels compared to WT and CB2R-KO mice (**Fig. 4E, F**), suggesting a heightened systemic inflammatory response. This excessive inflammation likely contributes to the increased severity of infection observed in CB1R-KO mice. While CB2R-KO mice also showed elevated TNF- α levels, the increase was less pronounced, suggesting a distinct role for CB1R in modulating inflammatory responses. Survival analysis demonstrated the protective role of CB1R in host defense. WT mice had the highest survival rate (~80%) over the 4-day post-infection period, whereas both CB1R-KO and CB2R-KO mice showed significantly reduced survival, with CB1R-KO mice exhibiting the most severe vulnerability in this systemic model of *Salmonella* infection (**Fig. 4G**).

Host microbiome alterations in CB2R mice during infection

Although our study primarily focused on the role of CB1R and CB2R in immune responses during *Salmonella* infection, we observed that CB2R-KO mice exhibited worse infection outcomes despite showing no significant differences in bacterial dissemination to organs or intracellular bacterial burden in macrophages. This unexpected finding led us to explore potential alternative factors that could contribute to the heightened susceptibility of CB2R-KO mice. Given the well-established role of the gut microbiome in shaping immune responses³⁰ and host defense mechanisms against *Salmonella*³¹⁻³⁵, we hypothesized that CB2R deficiency may alter gut microbial composition in a way that may influence susceptibility to infection. The endocannabinoids are known to regulate gut homeostasis and microbiome³⁶, making it plausible that loss of CB2R could drive specific microbiome alterations that contribute to immune dysregulation or nutritional landscape. To investigate this possibility, we performed a comparative microbiome analysis in CB2R-KO and WT mice, assessing microbial diversity and composition before and after *Salmonella* infection. The analysis revealed distinct differences in microbiome composition between the two groups, although no significant differences were observed in overall diversity (Shannon diversity index, $p=0.32$) (**Fig. 5A**). Notably, the abundance of beneficial gut bacteria, including *Lactobacillus acidophilus*, *L. intestinalis*, *L. gasseri*, *L. crispatus*, and *Bifidobacterium animalis*, was significantly reduced in CB2R-KO mice compared to WT controls (**Fig. 5B**). These species are known to promote gut barrier integrity, enhance anti-inflammatory responses, and contribute to pathogen resistance. Conversely, CB2R-KO mice exhibited a significant enrichment of *Alistipes* species (*A. humii*, *A. finegoldii*, *A. onderdonkii*), which have been associated with both beneficial and pro-inflammatory effects, metabolic dysfunction, and colorectal cancer (**Fig. 5C**). During infection, pathway enrichment analysis revealed a marked downregulation of key metabolic pathways in CB2R-KO mice, including the *Bifidobacterium* shunt, *L-glutamine biosynthesis III*, and *L-lysine biosynthesis II*, while the *preQ0 biosynthesis* pathway was also significantly decreased compared to wild-type animals (**Fig. 6**). These findings indicate that CB2R deficiency reshapes the gut microbiota during *Salmonella* infection, potentially increasing host susceptibility. Further studies should determine how these microbial shifts impair immune defense against *Salmonella* in CB2R-KO mice.

Discussion

Successful defense against *Salmonella* infection requires a finely tuned immune response—excessive inflammation can lead to host tissue damage, while an insufficient response permits bacterial survival and dissemination³⁷. Our study demonstrates that CB1R and CB2R serve distinct and non-redundant roles in regulating host innate immunity and resilience to *Salmonella* infection. The absence of either receptor results in immune dysregulation and worsened infection

outcomes through different mechanisms: CB1R deficiency drives excessive inflammation and weight loss in infected animals, whereas CB2R deficiency disrupts immune homeostasis and induces functional microbiota alterations that may exacerbate infection susceptibility.

CB1R: a double-edged sword in host defense

CB1R has been extensively characterized in the central nervous system (CNS)^{38,39}, but it also modulates immune cells such as macrophages⁴⁰. Its activation by Δ^9 -THC, the psychoactive component of *Cannabis sativa*^{41,42}, or endogenous ligands such as AEA and 2-AG⁴³. Mechanistically, CB1R activation suppresses adenylate cyclase activity⁴⁴⁻⁴⁶ and can regulate calcium and potassium channels⁴⁷, influencing both phagocytic capacity⁴⁰ and cytokine output⁴⁸. Although CB1R can promote an inflammatory response under certain conditions^{49,50}, it can also limit excessive inflammation, as evidenced by the effects of agonists like WIN 55212-2 on reducing cytokine production and inflammasome activation^{12,51,52}.

In our study, CB1R deficiency resulted in increased systemic inflammation, pronounced weight loss, and reduced survival in *Salmonella*-infected mice. Despite this heightened inflammatory backdrop, CB1R-KO macrophages also exhibited a mixed or “M2b-like” phenotype, marked by elevated TGF- β and IL-6 alongside reduced IL-10. This pattern is consistent with M2b macrophages, which can produce both pro-inflammatory (e.g., IL-6, TNF- α) and anti-inflammatory (e.g., IL-10) mediators⁵³. However, in our CB1R-KO cells, IL-10 levels were paradoxically lower, suggesting a dysregulated M2b-like state in which certain anti-inflammatory mechanisms (IL-10) are diminished, yet TGF- β is high enough to suppress effective antimicrobial functions (e.g., NO production via iNOS)⁵⁴. This apparent contradiction—simultaneous hyperinflammation at the systemic level but reduced IL-10 and increased TGF- β at the cellular level—can be explained by the functionally wide-ranging nature of M2b macrophages, which can drive persistent, low-level inflammation while also impairing pathogen clearance^{53,55,56}. Indeed, *Salmonella* has been shown to exploit M2-like phenotypes to establish chronic infections, leveraging changes in lipid metabolism and membrane trafficking⁵³. Our findings thus suggest that CB1R normally helps orchestrate a more balanced macrophage response: in its absence, macrophages become skewed toward a dysfunctional M2b-like state that fails to eradicate bacteria effectively and contributes to overall immune dysregulation. Thus, CB1R signaling plays a dual role in infection control, both promoting bacterial clearance and preventing excessive inflammation. Its absence skews macrophage polarization in a way that favors *Salmonella* persistence, identifying CB1R as a potential target for immunomodulatory therapies.

In addition to modulating macrophage responses, our data suggest that CB1R deficiency may also significantly impair neutrophil recruitment to infected tissues. Although evidence is limited, previous studies have linked CB1R to neutrophil chemotaxis. For instance, activation of CB1R with the agonist ACEA was found to promote neutrophil chemotaxis—a response that can be inhibited by the CB1R antagonist AM281⁵⁷. In CB1R-KO mice, the marked reduction of neutrophils in affected tissues indicates that impaired chemotaxis or adhesion may be a key contributor to the observed phenotype. This finding points to an alternative mechanism by which CB1R signaling enhances host defense—not only by modulating macrophage polarization, which could be secondary effect, but also by facilitating effective neutrophil trafficking. Further investigation into the chemokines, adhesion molecules, and signaling pathways driving neutrophil recruitment at specific time points in CB1R-deficient genotype is warranted.

CB2R deficiency disrupts immune homeostasis and the gut microbiota

CB2R-KO mice exhibited a hyperinflammatory M1a-like macrophage phenotype, marked by increased IL-6 levels and a significant reduction in IL-10. Unlike CB1R-KO mice, CB2R-KO macrophages did not show elevated TGF- β , indicating a lack of compensatory immunosuppression. This reinforces CB2R’s established role in curbing excessive immune activation and promoting an M2 phenotype^{8,9,11,12,20}. Additionally, CB2R-KO mice showed increased neutrophil recruitment, yet this did not enhance bacterial clearance. Instead, excessive

neutrophil infiltration likely contributed to tissue damage rather than effective pathogen control, supporting CB2R's function as a negative regulator of neutrophil-driven inflammation²⁰.

Despite no significant differences in bacterial dissemination to organs, CB2R-KO mice exhibited worse infection outcomes, prompting an investigation into alternative contributors to disease severity. Microbiome analysis revealed significant alterations in gut bacterial composition in CB2R-KO mice. Notably, beneficial *Limosilactobacillus reuteri*, *Lactobacillus acidophilus*, *L. intestinalis*, *L. brevis*, and *Bifidobacterium animalis*, which support gut barrier integrity⁵⁸ and production of anti-inflammatory cytokines⁵⁸⁻⁵⁹, were significantly reduced in CB2R-KO mice after infection. The loss of these protective microbes may compromise gut homeostasis, heightening inflammation and impairing immune tolerance. Conversely, *Alistipes finegoldii*, *A. onderdonkii*, and *Alistipes megaguti* were significantly enriched in CB2R-KO mice. While *Alistipes* species have been associated with beneficial effects in some diseases, they have also been linked to heightened inflammation, metabolic dysfunction, and colorectal cancer⁶⁰⁻⁶².

Functional microbiome analysis revealed a downregulation of key metabolic pathways, including *Bifidobacterium* shunt activity and amino acid biosynthesis, further supporting the role of CB2R in shaping microbial functional capacity and its potential impact on immune responses. *Bifidobacterium* species and their metabolic products, particularly short-chain fatty acids (SCFAs), are well-documented immunomodulators that enhance gut barrier integrity and pathogen resistance. The *Bifidobacterium* shunt, a crucial metabolic pathway for SCFA production from oligosaccharides⁶³, is notably depleted in dysbiotic conditions^{64,65}. Similarly, reduced biosynthesis of L-glutamine⁶⁶, which is essential for epithelial repair, suggests a potential mechanism for impaired mucosal defenses in CB2R-KO mice. Additionally, lysine has been shown to alleviate DSS-induced colitis by reducing inflammation, strengthening the intestinal barrier, and modulating immune cell populations—specifically increasing CD103+ dendritic cells (DCs) and regulatory T cells (Tregs) while decreasing Th1/Th2/Th17 cells⁶⁷. The observed reduction in L-lysine levels in CB2R-KO mice may contribute to a diminished protective and anti-inflammatory environment, further linking CB2R signaling to immune regulation through microbial-derived metabolites.

Collectively, these findings indicate that CB2R signaling contributes to gut microbiome stability during *Salmonella* infection, and its absence is associated with microbial dysbiosis and altered immune responses. Further investigation is needed to determine whether specific microbial shifts contribute to the heightened disease severity observed in CB2R-KO mice.

Possible therapeutic implications and conclusion

The distinct roles of CB1R and CB2R in regulating immune responses, inflammation, and gut microbiome composition present promising opportunities for therapeutic intervention. Modulating these pathways could potentially provide supporting strategies to improve infection outcomes.

For example, enhancing CB1R activity may help mitigate excessive inflammation, minimize tissue damage, and improve survival during *Salmonella* infection. However, our findings indicate that CB1R deficiency not only exacerbates systemic inflammation but also impairs bacterial clearance by skewing macrophages toward a dysregulated polarization state that combines M1-like features with an M2b-like profile, and by reducing neutrophil recruitment. Thus, therapeutic strategies targeting CB1R must carefully balance immune suppression to avoid creating a permissive environment for pathogen persistence. Notably, prior studies have demonstrated context-dependent effects of CB1R modulation— Δ^9 -THC, a CB1R agonist, has been shown to influence cytokine production in *Legionella pneumophila* infection by increasing TNF- α and IL-6 levels²³ while CB1R blockade with the antagonist SR141716A enhanced macrophage antimicrobial activity in *Brucella suis* infection²¹. Conversely, CB2R activation appears to be more directly linked to restoring immune homeostasis, particularly in settings where excessive inflammation contributes to immunopathology. Our data show that CB2R deficiency leads to gut microbiome dysbiosis and a more straightforward M1-like pro-inflammatory macrophage phenotype, with

reduced IL-10, increased CD86, and diminished CD206 expression. These observations suggest that CB2R-targeted therapies could help maintain microbiota-mediated protective mechanisms and mitigate infection-induced dysregulation. Consistent with this view, previous studies have shown that activation of CB2R by compounds such as JWH133 reduces neutrophil recruitment, NF- κ B signaling, and NLRP3 inflammasome activation²⁰, supporting its role in preventing excessive immune activation.

Conclusions

Our study reveals distinct yet complementary roles of CB1R and CB2R in immune regulation and host-pathogen interactions during *Salmonella* infection. CB1R modulates both the inflammatory response and macrophage polarization, while CB2R plays a key role in maintaining immune homeostasis and gut microbiota balance. The absence of either receptor leads to immune dysregulation, microbial shifts, and worsened infection outcomes. These findings underscore the potential of cannabinoid receptor signaling as a novel factor in host defense and suggest that targeting CB1R and CB2R—potentially in combination with microbiome-based interventions—could offer innovative therapeutic strategies against bacterial infections.

Materials and Methods

Bacterial strains

Salmonella enterica serovar Typhimurium strain 12023 was used for murine studies and *Salmonella* Typhimurium strain UK-1 was used for cell infections. For murine studies, the bacteria were cultured in Luria-Bertani (LB) Lennox broth at 37°C with shaking until they reached mid-log growth [OD₆₀₀ nm = 0.75]. For cell culture infections, the bacteria were cultured in LB Lennox broth at 37°C with shaking until they reached OD₆₀₀ nm = 0.5. Bacteria were then harvested, washed with phosphate-buffered saline (PBS), and resuspended in PBS to the appropriate concentration for infection.

Animals

CB1 receptor knockout (CB1R-KO) and CB2 receptor knockout (CB2R-KO) mice on a C57BL/6 background were used for all experiments. Mice were housed under specific pathogen-free conditions with ad libitum access to food and water. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Florida and conducted in accordance with relevant guidelines.

Salmonella infection in mice

Male and female C57BL/6 mice (8–12 weeks old) from the holding colony were randomly assigned to infection groups. When possible, littermate controls were used to minimize microbiota-related variations in *Salmonella* colonization. Mice were orally infected with *Salmonella* Typhimurium (7.5×10^7 CFU) in 50 μ L PBS using a gavage needle, while control mice received PBS alone. Infections were monitored for four days post-infection.

Mice were observed daily for clinical signs of infection, including weight loss and body condition, using a standardized scoring system. Weight and body scores were recorded daily for up to 14 days post-infection. To assess survival, mice were monitored for 14 days post-infection. Survival rates were recorded daily. Mice were euthanized if they exhibited severe clinical symptoms, in accordance with IACUC guidelines. Survival curves were generated using the Kaplan-Meier method, and statistical significance was determined using the log-rank (Mantel-Cox) test.

For experiments requiring tissue analysis, mice were euthanized at four days post-infection, and liver and spleen tissues were aseptically collected. Tissues were homogenized in sterile PBS using a TissueLyser LT (Qiagen), and serial dilutions were plated on LB agar. After 24 hours of incubation at 37°C, CFUs were counted to quantify bacterial load in each organ.

Flow cytometry

Spleens were collected from both infected and control mice, and single-cell suspensions were prepared by mechanically dissociating the tissues through a 70 μ m cell strainer. Red blood cells were lysed using RBC Lysis Buffer (Invitrogen), and the remaining cells were incubated with a Live/Dead viability dye (Zombie Aqua) at 4°C for 15 minutes. After washing with FACS buffer (PBS containing 1% BSA), the cells were treated with Fc Block (TruStain fcX anti-mouse CD16/32, BioLegend) for 5 minutes to minimize non-specific binding. Surface marker staining was performed by incubating the cells with an antibody cocktail targeting specific surface markers at 4°C for 30 minutes. Following another wash with FACS buffer, cells were fixed with Cytofix/Cytoperm solution (BD Biosciences) for 15 minutes. Fixed cells were washed twice with Perm/Wash buffer (BD Biosciences) before staining for intracellular markers. Flow cytometric data were acquired using the CytoFLEX flow cytometer (Beckman Coulter) and analyzed using FlowJo software (Tree Star, Inc.).

Flow cytometry was then used to characterize immune cell populations and their functional states in spleens from infected and control mice using multiple staining panels. For the identification of lymphoid and myeloid cell populations, single-cell suspensions were stained with CD45 (Pacific Blue, Cat# 157212) as a leukocyte marker, Zombie Aqua (Cat#77143) for viability, CD3 (PerCP/Cy5.5, Cat# 100217) for T cells, CD19 (APC/Fire750, Cat# 115557) for B cells, CD11b (Alexa Fluor 647, Cat# 101218) for myeloid cells, NK1.1 (Alexa Fluor 700, Cat# 156511) for natural killer (NK) cells, F4/80 (PE, Cat# 123109) for macrophages, and Ly6G (Alexa Fluor 488, Cat# 127625) for neutrophils. A second panel was used to evaluate the activation and polarization of myeloid cells, incorporating CD86 (Pacific Blue, Cat# 105021) as an activation marker for antigen-presenting cells and CD206 (Alexa Fluor 700, Cat# 141733) for M2 macrophages, alongside the same markers for other immune subsets. A separate panel was designed to detect intracellular *Salmonella*, using CD45 and CD11b to gate on leukocytes and myeloid cells, F4/80 to identify macrophages, and a FITC-conjugated *Salmonella*-specific antibody (Invitrogen, Ref # PA1-73020) to detect intracellular bacteria. Cytokine production was assessed using a panel that included IL-6 (PE, Cat# 504504) as pro-inflammatory markers, and IL-10 (Alexa Fluor 488, Cat# 505013) and TGF- β 1 (PerCP/Cy5.5, Cat# 141410) as anti-inflammatory markers, in addition to CD45, CD11b, and F4/80 to identify macrophages. All antibodies were purchased from BioLegend, except for the *Salmonella*-specific antibody (Invitrogen).

Cytokine measurements

Blood was collected from both infected and control mice at the indicated time points via saphenous vein bleeding. Blood samples were centrifugation at 10,000 $\times$ g for 10 minutes at 4°C to separate the serum. The samples were then stored in -20C until further use. The levels of TNF- α and IL-1 β in the serum were quantified using specific ELISA kits (R&D Biosystems) according to the manufacturer's instructions.

BMDM cell culture and infection

Bone marrow-derived macrophages (BMDMs) were generated from mesenchymal stem cells isolated from the hindlimbs of wild-type C57BL/6 mice. Cells were cultured in RPMI 1640 supplemented with macrophage colony-stimulating factor (M-CSF) (25 ng/ml) to promote differentiation into macrophages. The culture medium, including M-CSF, was refreshed every three days, and BMDMs were considered mature on day 7. For infections, BMDMs were seeded at 6×10^5 cells per well in 12-well plates and allowed to adhere for 24 hours before infection. *Salmonella enterica* serovar Typhimurium strain UK-1 was grown overnight in Lennox LB broth (16 hours, 37°C, shaking). A subculture was established in fresh Lennox LB broth (25 mL) and grown to an optical density (OD600) of 0.5 to ensure bacteria were in the mid-logarithmic growth phase. BMDMs were infected with *Salmonella* at MOI of 10 in incomplete RPMI 1640 for 1 hour. Following infection, cells were washed with PBS and incubated in RPMI supplemented with gentamicin (100 μ g/mL) for 1 hour to eliminate extracellular bacteria. The medium was then

replaced with RPMI containing gentamicin (25 µg/mL), and cells were incubated until designated time points. Cell pellets were stored in RNeasy for downstream analyses.

Microbiome analysis

Mice were placed in sterile containers for stool collection, which was performed the day before infection (baseline) and four days post-infection. Stool samples were collected using sterile tools and immediately transferred into sterile Transnetix tubes containing DNA stabilization buffer. Samples were temporarily stored at 4°C before being shipped under controlled conditions to Transnetix for processing the following day. Microbiota profiling was conducted using shallow shotgun whole-genome sequencing on an *Illumina* platform (1×150 bp). Raw sequencing reads were processed to remove low-quality sequences (expected error >0.5) and fragments shorter than 150 bp using Vsearch⁶⁸. High-quality sequences were then taxonomically classified using Kraken 2⁶⁹ with the standard database. The resulting contingency table was converted into a phyloseq object for downstream analyses⁷⁰. To ensure uniform sequencing depth across samples, data were rarefied to a minimum library size of 1,609,000 reads per sample. Alpha diversity metrics were calculated using the microbiome package in R. Boxplots summarizing alpha diversity distributions were generated using *ggplot2*⁷¹, and statistical significance was assessed using the Kruskal-Wallis test from base R. Differential abundance analysis was performed using the ALDEx2 package⁷². Sequence files were processed to remove low-quality sequences (expected error >0.5) and sequences smaller than 150bp using Vsearch. The remaining high-quality sequences were classified using Kraken 2 and the standard database. The resulting contingency table was converted into a phyloseq object for downstream analyses. Data were rarefied by the minimum library size of 1,609,000 per sample. Alpha diversity was measured by using the rarefied dataset with the microbiome package. Boxplots summarizing the alpha diversity distribution were plotted by using *ggplot2* R package. The significance of numerical evaluations of alpha diversity was tested with the Kruskal-Wallis from base R. The ALDEx2 package was used to calculate differential abundance. Functional microbiome analysis was conducted with HUMAnN 3.0 to identify shifts in metabolic pathways⁷³.

qPCR analysis

Cells were collected via cell scraping, resuspended in RNeasy (Thermo Fisher Scientific), and stored at -20°C until further processing. Total RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen), following the manufacturer's instructions. RNA concentration and purity were assessed using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Complementary DNA (cDNA) was synthesized from 1 µg of total RNA using the iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad). Quantitative real-time PCR (RT-qPCR) was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) on a CFX96 Real-Time System (Biorad). Primer sequences for *Cnr1* (Cat #10025636) and *Cnr2* (Cat #10041595) were obtained from the PrimePCR SYBR Green Assay (Bio-Rad). Melt-curve analysis was conducted to verify primer specificity and amplification efficiency. Relative gene expression was calculated using the $\Delta\Delta C_t$ method, with β -actin as the internal reference control.

Statistical analysis

Data are presented as mean $\pm$ SEM. Statistical significance between groups was evaluated using Student's t-test or one-way ANOVA followed by Tukey's post-hoc test for multiple comparisons, as appropriate. A p-value of <0.05 was considered statistically significant.

Data Availability Statement

All data generated or analyzed during this study are included in the manuscript and its supporting information files.

Acknowledgments

M.J.F. was funded by 2021 Research Grants Program of the Consortium for Medical Marijuana Clinical Outcomes Research, which is funded through State of Florida appropriations, as well as R01 AI158749-03 from the U.S. National Institute of Allergy and Infectious Diseases (NIAID). H.A. B. was supported by 5T32AI007110-38 from the National Institute of Allergy and Infectious Diseases.

References

- McCabe, S.E., Arterberry, B.J., Dickinson, K., Evans-Polce, R.J., Ford, J.A., Ryan, J.E., and Schepis, T.S. (2021). Assessment of Changes in Alcohol and Marijuana Abstinence, Co-Use, and Use Disorders Among US Young Adults From 2002 to 2018. *JAMA Pediatr* 175, 64-72. 10.1001/jamapediatrics.2020.3352.
- Bow, E.W., and Rimoldi, J.M. (2016). The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. *Perspect Medicin Chem* 8, 17-39. 10.4137/PMC.S32171.
- Hillard, C.J. (2000). Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. *Prostaglandins Other Lipid Mediat* 61, 3-18. 10.1016/S0090-6980(00)00051-4.
- Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258, 1946-1949. 10.1126/science.1470919.
- Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., and Compton, D.R. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50, 83-90.
- Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., and Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun* 215, 89-97. 10.1006/bbrc.1995.2437.
- Tarique, A.A., Evron, T., Zhang, G., Tepper, M.A., Morshed, M.M., Andersen, I.S.G., Begum, N., Sly, P.D., and Fantino, E. (2020). Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis. *J Cyst Fibros* 19, 823-829. 10.1016/j.jcf.2020.03.015.
- Rzeczycki, P., Rasner, C., Lammlin, L., Junginger, L., Goldman, S., Bergman, R., Redding, S., Knights, A.J., Elliott, M., and Maerz, T. (2021). Cannabinoid receptor type 2 is upregulated in synovium following joint injury and mediates anti-inflammatory effects in synovial fibroblasts and macrophages. *Osteoarthritis Cartilage* 29, 1720-1731. 10.1016/j.joca.2021.09.003.
- Louvet, A., Teixeira-Clerc, F., Chobert, M.N., Deveau, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A., and Lotersztajn, S. (2011). Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. *Hepatology* 54, 1217-1226. 10.1002/hep.24524.
- Jiang, F., Xia, M., Zhang, Y., Chang, J., Cao, J., Zhang, Z., Qian, Z., and Yang, L. (2022). Cannabinoid receptor-2 attenuates neuroinflammation by promoting autophagy-mediated degradation of the NLRP3 inflammasome post spinal cord injury. *Front Immunol* 13, 993168. 10.3389/fimmu.2022.993168.
- Tomar, S., Zumbrun, E.E., Nagarkatti, M., and Nagarkatti, P.S. (2015). Protective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs. *J Pharmacol Exp Ther* 353, 369-379. 10.1124/jpet.114.220368.

- 565 12. Braun, M., Khan, Z.T., Khan, M.B., Kumar, M., Ward, A., Achyut, B.R., Arbab, A.S., Hess,
566 D.C., Hoda, M.N., Baban, B., et al. (2018). Selective activation of cannabinoid receptor-2
567 reduces neuroinflammation after traumatic brain injury via alternative macrophage
568 polarization. *Brain Behav Immun* 68, 224-237. 10.1016/j.bbi.2017.10.021.
- 569 13. Barker, H., and Ferraro, M.J. (2024). Exploring the versatile roles of the endocannabinoid
570 system and phytocannabinoids in modulating bacterial infections. *Infect Immun* 92,
571 e0002024. 10.1128/iai.00020-24.
- 572 14. Wassmann, C.S., Højrup, P., and Klitgaard, J.K. (2020). Cannabidiol is an effective
573 helper compound in combination with bacitracin to kill Gram-positive bacteria. *Sci Rep*
574 10, 4112. 10.1038/s41598-020-60952-0.
- 575 15. Hu, D.L., Zhu, G., Mori, F., Omoe, K., Okada, M., Wakabayashi, K., Kaneko, S.,
576 Shinagawa, K., and Nakane, A. (2007). Staphylococcal enterotoxin induces emesis
577 through increasing serotonin release in intestine and it is downregulated by cannabinoid
578 receptor 1. *Cell Microbiol* 9, 2267-2277. 10.1111/j.1462-5822.2007.00957.x.
- 579 16. Poulsen, J.S., Nielsen, C.K., Pedersen, N.A., Wimmer, R., Sondergaard, T.E., de Jonge,
580 N., and Nielsen, J.L. (2023). Proteomic Changes in Methicillin-Resistant. *J Nat Prod* 86,
581 1690-1697. 10.1021/acs.jnatprod.3c00064.
- 582 17. Galletta, M., Reekie, T.A., Nagalingam, G., Bottomley, A.L., Harry, E.J., Kassiou, M., and
583 Triccas, J.A. (2020). Rapid Antibacterial Activity of Cannabichromenic Acid against
584 Methicillin-Resistant. *Antibiotics (Basel)* 9. 10.3390/antibiotics9080523.
- 585 18. Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., Smith, E., and
586 Rahman, M.M. (2008). Antibacterial cannabinoids from *Cannabis sativa*: a structure-
587 activity study. *J Nat Prod* 71, 1427-1430. 10.1021/np8002673.
- 588 19. Morahan, P.S., Klykken, P.C., Smith, S.H., Harris, L.S., and Munson, A.E. (1979). Effects
589 of cannabinoids on host resistance to *Listeria monocytogenes* and herpes simplex virus.
590 *Infect Immun* 23, 670-674.
- 591 20. Nagre, N., Nicholson, G., Cong, X., Lockett, J., Pearson, A.C., Chan, V., Kim, W.K.,
592 Vinod, K.Y., and Catravas, J.D. (2022). Activation of cannabinoid-2 receptor protects
593 against *Pseudomonas aeruginosa* induced acute lung injury and inflammation. *Respir*
594 *Res* 23, 326. 10.1186/s12931-022-02253-w.
- 595 21. Gross, A., Terraza, A., Marchant, J., Bouaboula, M., Ouahrani-Bettache, S., Liautard,
596 J.P., Casellas, P., and Dornand, J. (2000). A beneficial aspect of a CB1 cannabinoid
597 receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the
598 intracellular pathogen *Brucella suis*. *J Leukoc Biol* 67, 335-344. 10.1002/jlb.67.3.335.
- 599 22. Chouinard, F., Turcotte, C., Guan, X., Larose, M.C., Poirier, S., Bouchard, L., Provost, V.,
600 Flamand, L., Grandvaux, N., and Flamand, N. (2013). 2-Arachidonoyl-glycerol- and
601 arachidonic acid-stimulated neutrophils release antimicrobial effectors against *E. coli*, *S.*
602 *aureus*, HSV-1, and RSV. *J Leukoc Biol* 93, 267-276. 10.1189/jlb.0412200.
- 603 23. Klein, T.W., Newton, C., Widen, R., and Friedman, H. (1993). Delta 9-
604 tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with
605 *Legionella pneumophila*. *J Pharmacol Exp Ther* 267, 635-640.
- 606 24. Newton, C.A., Chou, P.J., Perkins, I., and Klein, T.W. (2009). CB(1) and CB(2)
607 cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-
608 induced T helper cell shift following immune activation by *Legionella pneumophila*
609 infection. *J Neuroimmune Pharmacol* 4, 92-102. 10.1007/s11481-008-9126-2.
- 610 25. Ellermann, M., Pacheco, A.R., Jimenez, A.G., Russell, R.M., Cuesta, S., Kumar, A., Zhu,
611 W., Vale, G., Martin, S.A., Raj, P., et al. (2020). Endocannabinoids Inhibit the Induction of
612 Virulence in Enteric Pathogens. *Cell* 183, 650-665.e615. 10.1016/j.cell.2020.09.022.
- 613 26. Sheppe, A.E.F., Kummari, E., Walker, A., Richards, A., Hui, W.W., Lee, J.H., Mangum,
614 L., Borazjani, A., Ross, M.K., and Edelman, M.J. (2018). PGE2 Augments
615 Inflammasome Activation and M1 Polarization in Macrophages Infected With *Salmonella*
616 *Typhimurium* and *Yersinia enterocolitica*. *Front Microbiol* 9, 2447.
617 10.3389/fmicb.2018.02447.

- 618 27. Lee, J.H., Hou, X., Kummari, E., Borazjani, A., Edelmann, M.J., and Ross, M.K. (2017).
619 Endocannabinoid hydrolases in avian HD11 macrophages identified by
620 chemoproteomics: inactivation by small-molecule inhibitors and pathogen-induced
621 downregulation of their activity. *Mol Cell Biochem.* 10.1007/s11010-017-3237-0.
- 622 28. Sheppe, A.E.F., and Edelmann, M.J. (2021). Roles of eicosanoids in regulating
623 inflammation and neutrophil migration as an innate host response to bacterial infections.
624 *Infect Immun.* 10.1128/IAI.00095-21.
- 625 29. Lee, J.H., Hou, X., Kummari, E., Borazjani, A., Edelmann, M.J., and Ross, M.K. (2018).
626 Endocannabinoid hydrolases in avian HD11 macrophages identified by
627 chemoproteomics: inactivation by small-molecule inhibitors and pathogen-induced
628 downregulation of their activity. *Mol Cell Biochem* 444, 125-141. 10.1007/s11010-017-
629 3237-0.
- 630 30. Miller, B.M., and Bäuml, A.J. (2021). The Habitat Filters of Microbiota-Nourishing
631 Immunity. *Annu Rev Immunol* 39, 1-18. 10.1146/annurev-immunol-101819-024945.
- 632 31. Ahmer, B.M., and Gunn, J.S. (2011). Interaction of *Salmonella* spp. with the Intestinal
633 Microbiota. *Front Microbiol* 2, 101. 10.3389/fmicb.2011.00101.
- 634 32. Gül, E., Bakkeren, E., Salazar, G., Steiger, Y., Abi Younes, A., Clerc, M., Christen, P.,
635 Fattinger, S.A., Nguyen, B.D., Kiefer, P., et al. (2023). The microbiota conditions a gut
636 milieu that selects for wild-type *Salmonella* Typhimurium virulence. *PLoS Biol* 21,
637 e3002253. 10.1371/journal.pbio.3002253.
- 638 33. Rivera-Chávez, F., Zhang, L.F., Faber, F., Lopez, C.A., Byndloss, M.X., Olsan, E.E., Xu,
639 G., Velazquez, E.M., Lebrilla, C.B., Winter, S.E., and Bäuml, A.J. (2016). Depletion of
640 Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic Luminal
641 Expansion of *Salmonella*. *Cell Host Microbe* 19, 443-454. 10.1016/j.chom.2016.03.004.
- 642 34. Stecher, B., Robbiani, R., Walker, A.W., Westendorf, A.M., Barthel, M., Kremer, M.,
643 Chaffron, S., Macpherson, A.J., Buer, J., Parkhill, J., et al. (2007). *Salmonella* enterica
644 serovar typhimurium exploits inflammation to compete with the intestinal microbiota.
645 *PLoS Biol* 5, 2177-2189. 10.1371/journal.pbio.0050244.
- 646 35. Thiennittr, P., Winter, S.E., and Bäuml, A.J. (2012). *Salmonella*, the host and its
647 microbiota. *Curr Opin Microbiol* 15, 108-114. 10.1016/j.mib.2011.10.002.
- 648 36. Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A.T., Basu, S., and Srivastava,
649 P.K. (2017). Endocannabinoid system acts as a regulator of immune homeostasis in the
650 gut. *Proc Natl Acad Sci U S A* 114, 5005-5010. 10.1073/pnas.1612177114.
- 651 37. Behnsen, J., Perez-Lopez, A., Nuccio, S.P., and Raffatellu, M. (2015). Exploiting host
652 immunity: the *Salmonella* paradigm. *Trends Immunol* 36, 112-120.
653 10.1016/j.it.2014.12.003.
- 654 38. Glass, M., Dragunow, M., and Faull, R.L. (1997). Cannabinoid receptors in the human
655 brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal
656 and adult human brain. *Neuroscience* 77, 299-318. 10.1016/s0306-4522(96)00428-9.
- 657 39. Herkenham, M., Groen, B.G., Lynn, A.B., De Costa, B.R., and Richfield, E.K. (1991).
658 Neuronal localization of cannabinoid receptors and second messengers in mutant mouse
659 cerebellum. *Brain Res* 552, 301-310. 10.1016/0006-8993(91)90096-e.
- 660 40. Mai, P., Tian, L., Yang, L., Wang, L., and Li, L. (2015). Cannabinoid receptor 1 but not 2
661 mediates macrophage phagocytosis by G α i/o/RhoA/ROCK signaling pathway. *J Cell*
662 *Physiol* 230, 1640-1650. 10.1002/jcp.24911.
- 663 41. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M., and Bonner, T.I. (1999).
664 Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout
665 mice. *Proc Natl Acad Sci U S A* 96, 5780-5785. 10.1073/pnas.96.10.5780.
- 666 42. Schurman, L.D., Lu, D., Kendall, D.A., Howlett, A.C., and Lichtman, A.H. (2019).
667 Molecular Mechanism and Cannabinoid Pharmacology. In *Substance Use Disorders*,
668 M.A. Nader, and Y.L. Hurd, eds. (Springer International Publishing), pp. 323-353.
- 669 43. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder,
670 C.C., Herkenham, M., Mackie, K., Martin, B.R., et al. (2002). International Union of

671 Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* 54, 161-
672 202. 10.1124/pr.54.2.161.

673 44. Herrera, B., Carracedo, A., Diez-Zaera, M., Guzmán, M., and Velasco, G. (2005). p38
674 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. *FEBS*
675 *Lett* 579, 5084-5088. 10.1016/j.febslet.2005.08.021.

676 45. Saroz, Y., Kho, D.T., Glass, M., Graham, E.S., and Grimsey, N.L. (2019). Cannabinoid
677 Receptor 2 (CB₂). *ACS Pharmacol Transl Sci* 2, 414-428. 10.1021/acspsci.9b00049.

678 46. Dalton, G.D., and Howlett, A.C. (2012). Cannabinoid CB₁ receptors transactivate multiple
679 receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in
680 neuronal cells. *Br J Pharmacol* 165, 2497-2511. 10.1111/j.1476-5381.2011.01455.x.

681 47. Kreitzer, A.C., Carter, A.G., and Regehr, W.G. (2002). Inhibition of interneuron firing
682 extends the spread of endocannabinoid signaling in the cerebellum. *Neuron* 34, 787-796.
683 10.1016/s0896-6273(02)00695-5.

684 48. Shiratsuchi, A., Watanabe, I., Yoshida, H., and Nakanishi, Y. (2008). Involvement of
685 cannabinoid receptor CB₂ in dectin-1-mediated macrophage phagocytosis. *Immunology*
686 *& Cell Biology* 86, 179-184. 10.1038/sj.icb.7100121.

687 49. Deng, Y.M., Zhao, C., Wu, L., Qu, Z., and Wang, X.Y. (2022). Cannabinoid Receptor-1
688 suppresses M2 macrophage polarization in colorectal cancer by downregulating EGFR.
689 *Cell Death Discov* 8, 273. 10.1038/s41420-022-01064-8.

690 50. Tian, L., Li, W., Yang, L., Chang, N., Fan, X., Ji, X., Xie, J., and Li, L. (2017).
691 Cannabinoid Receptor 1 Participates in Liver Inflammation by Promoting M1 Macrophage
692 Polarization. *Front Immunol* 8, 1214. 10.3389/fimmu.2017.01214.

693 51. Pérez-Diego, M., Angelina, A., Martín-Cruz, L., de la Rocha-Muñoz, A., Maldonado, A.,
694 Sevilla-Ortega, C., and Palomares, O. (2023). Cannabinoid WIN55,212-2 reprograms
695 monocytes and macrophages to inhibit LPS-induced inflammation. *Front Immunol* 14,
696 1147520. 10.3389/fimmu.2023.1147520.

697 52. He, Q., Zhang, W., Zhang, J., and Deng, Y. (2022). Cannabinoid Analogue WIN 55212-2
698 Protects Paraquat-Induced Lung Injury and Enhances Macrophage M2 Polarization.
699 *Inflammation* 45, 2256-2267.

700 53. Taddeo, J.R., Wilson, N., Kowal, A., Beld, J., Andres, K.S., Tükel, Ç., and Tam, V.C.
701 (2024). PPAR α exacerbates. *Gut Microbes* 16, 2419567.
702 10.1080/19490976.2024.2419567.

703 54. Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q.W., and Nathan, C. (1993). Mechanisms of
704 suppression of macrophage nitric oxide release by transforming growth factor beta. *J Exp*
705 *Med* 178, 605-613. 10.1084/jem.178.2.605.

706 55. Panagi, I., Jennings, E., Zeng, J., Günster, R.A., Stones, C.D., Mak, H., Jin, E., Stapels,
707 D.A.C., Subari, N.Z., Pham, T.H.M., et al. (2020). Salmonella Effector SteE Converts the
708 Mammalian Serine/Threonine Kinase GSK3 into a Tyrosine Kinase to Direct Macrophage
709 Polarization. *Cell Host Microbe* 27, 41-53.e46. 10.1016/j.chom.2019.11.002.

710 56. Pham, T.H.M., Brewer, S.M., Thurston, T., Massis, L.M., Honeycutt, J., Lugo, K.,
711 Jacobson, A.R., Vilches-Moure, J.G., Hamblin, M., Helaine, S., and Monack, D.M. (2020).
712 Salmonella-Driven Polarization of Granuloma Macrophages Antagonizes TNF-Mediated
713 Pathogen Restriction during Persistent Infection. *Cell Host Microbe* 27, 54-67.e55.
714 10.1016/j.chom.2019.11.011.

715 57. Zhou, X., Yang, L., Fan, X., Zhao, X., Chang, N., and Li, L. (2020). Neutrophil
716 Chemotaxis and NETosis in Murine Chronic Liver Injury via Cannabinoid Receptor 1/ G α .
717 *Cells* 9. 10.3390/cells9020373.

718 58. Dempsey, E., and Corr, S.C. (2022). Lactobacillus spp. for Gastrointestinal Health:
719 Current and Future Perspectives. *Front Immunol* 13, 840245.
720 10.3389/fimmu.2022.840245.

721 59. Rastogi, S., and Singh, A. (2022). Gut microbiome and human health: Exploring how the
722 probiotic genus. *Front Pharmacol* 13, 1042189. 10.3389/fphar.2022.1042189.

723 60. Parker, B.J., Wearsch, P.A., Veloo, A.C.M., and Rodriguez-Palacios, A. (2020). The
724 Genus. *Front Immunol* 11, 906. 10.3389/fimmu.2020.00906.

725 61. Jang, J.H., Jang, S.Y., Ahn, S., Oh, J.Y., Yeom, M., Ko, S.J., Park, J.W., Kwon, S.K.,
726 Kim, K., Lee, I.S., et al. (2024). Chronic Gut Inflammation and Dysbiosis in IBS:
727 Unraveling Their Contribution to Atopic Dermatitis Progression. *Int J Mol Sci* 25.
728 10.3390/ijms25052753.

729 62. Jiang, W., Wu, N., Wang, X., Chi, Y., Zhang, Y., Qiu, X., Hu, Y., Li, J., and Liu, Y. (2015).
730 Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune
731 function in intestine of humans with non-alcoholic fatty liver disease. *Sci Rep* 5, 8096.
732 10.1038/srep08096.

733 63. Wolin, M.J., Zhang, Y., Bank, S., Yerry, S., and Miller, T.L. (1998). NMR detection of
734 ¹³CH₃¹³COOH from 3-¹³C-glucose: a signature for Bifidobacterium fermentation in the
735 intestinal tract. *J Nutr* 128, 91-96. 10.1093/jn/128.1.91.

736 64. Su, K.W., Cetinbas, M., Martin, V.M., Virkud, Y.V., Seay, H., Ndahayo, R., Rosow, R.,
737 Elkort, M., Gupta, B., Kramer, E., et al. (2023). Early infancy dysbiosis in food protein-
738 induced enterocolitis syndrome: A prospective cohort study. *Allergy* 78, 1595-1604.
739 10.1111/all.15644.

740 65. Wang, H., Yan, G., Wu, Y., Zhuoma, D., Liu, Z., Gao, X., and Wang, X. (2024). Fecal
741 microbiota related to postoperative endoscopic recurrence in patients with Crohn's
742 disease. *Gastroenterol Rep (Oxf)* 12, goae017. 10.1093/gastro/goae017.

743 66. Kuo, Y.R., Lin, C.H., Lin, W.S., and Pan, M.H. (2024). L-Glutamine Substantially
744 Improves 5-Fluorouracil-Induced Intestinal Mucositis by Modulating Gut Microbiota and
745 Maintaining the Integrity of the Gut Barrier in Mice. *Mol Nutr Food Res* 68, e2300704.
746 10.1002/mnfr.202300704.

747 67. Tang, Q., Fan, G., Peng, X., Sun, X., Kong, X., Zhang, L., Zhang, C., Liu, Y., Yang, J.,
748 Yu, K., et al. (2025). Gut bacterial L-lysine alters metabolism and histone methylation to
749 drive dendritic cell tolerance. *Cell Rep* 44, 115125. 10.1016/j.celrep.2024.115125.

750 68. Rognes, T., Flouri, T., Nichols, B., Quince, C., and Mahé, F. (2016). VSEARCH: a
751 versatile open source tool for metagenomics. *PeerJ* 4, e2584. 10.7717/peerj.2584.

752 69. Wood, D.E., Lu, J., and Langmead, B. (2019). Improved metagenomic analysis with
753 Kraken 2. *Genome Biol* 20, 257. 10.1186/s13059-019-1891-0.

754 70. McMurdie, P.J., and Holmes, S. (2013). phyloseq: an R package for reproducible
755 interactive analysis and graphics of microbiome census data. *PLoS One* 8, e61217.
756 10.1371/journal.pone.0061217.

757 71. Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis (Springer Publishing
758 Company, Incorporated).

759 72. Fernandes, A.D., Macklaim, J.M., Linn, T.G., Reid, G., and Gloor, G.B. (2013). ANOVA-
760 like differential expression (ALDEx) analysis for mixed population RNA-Seq. *PLoS One* 8,
761 e67019. 10.1371/journal.pone.0067019.

762 73. Beghini, F., McIver, L.J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S.,
763 Mailyan, A., Manghi, P., Scholz, M., Thomas, A.M., et al. (2021). Integrating taxonomic,
764 functional, and strain-level profiling of diverse microbial communities with bioBakery 3.
765 *Elife* 10. 10.7554/eLife.65088.

766

767

Figures

Figure 1: Roles of CB1R and CB2R deficiencies in modulating host resilience and survival against *Salmonella Typhimurium* infection in C57BL/6 mice. (A) Experimental setup illustrating the oral infection of wild-type (WT), CB1 receptor knockout (CB1R-KO), and CB2 receptor knockout (CB2R-KO) C57BL/6 mice with 7.5×10^7 CFUs of *Salmonella Typhimurium*. (B–F) Flow cytometry analysis of various immune cell subsets in the spleens of these mice post-infection, showing variations in the innate immune response across the three genotypes. Quantified cell populations include NK cells (B), CD3+ T cells (C), B cells (D), macrophages (E), and neutrophils (F). One-way ANOVA was used for statistical analysis. Statistical significance is denoted by asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. (G) Comparison of macrophage and neutrophil populations across WT, CB1R-KO, and CB2R-KO genotypes.

Figure 2. Cytokine expression in splenic macrophages in CB1R and CB2R knockout mice post-infection with *Salmonella Typhimurium*. Flow cytometry was used to quantify cytokine production in splenic macrophages (CD45⁺CD11b⁺F4/80⁺) from wild-type (WT), CB1 receptor knockout (CB1R-KO), and CB2 receptor knockout (CB2R-KO) C57BL/6 mice, 4 days post-infection with *Salmonella Typhimurium*. The following markers were analyzed: (A) IL-10, (B) IL-6, (C) TGF- β , (D) CD86, (E) TNF- α , and (F) CD206. Each bar graph represents the mean percentage $\pm$ SEM, with individual data points for each mouse. Statistical analyses were performed using one-way ANOVA to compare cytokine and marker expression levels between WT, CB1R-KO, and CB2R-KO groups. Statistical significance is denoted by asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. (G) Graphical summary of M1/M2 macrophage polarization markers in CB1R-KO and CB2R-KO splenic macrophages post-*Salmonella* infection, highlighting the receptor-specific shifts in immune phenotypes.

Figure 3. Influence of cannabinoid receptors on *Salmonella Typhimurium* dissemination in C57BL/6 mice. (A–C) Flow cytometry analysis of splenic cells from C57BL/6 mice infected with *Salmonella Typhimurium*, distinguishing CD45⁺ *Salmonella*⁺ cells to assess bacterial dissemination. (A) presents data from CD45⁺ cells, while (B) expands the analysis to all live cells, mapping the systemic spread of *Salmonella* in CB1R and CB2R knockout (CB1R-KO and CB2R-KO) mice compared to controls. (D) Colony-forming unit (CFU) plating of liver and spleen tissues from infected mice to quantify viable *Salmonella* loads. One-way ANOVA was used for statistical analysis. Statistical significance is indicated by asterisks: *p < 0.05, ****p < 0.0001.

Figure 4. Impact of CB1R and CB2R Knockout on *Salmonella* Infection Outcomes in Mice. (A) Body weight loss in wild-type (WT), CB1R knockout (CB1R-KO), and CB2R knockout (CB2R-KO) mice at 4 days post-infection (DPI) with *Salmonella Typhimurium*. (B) Body condition scores in WT, CB1R-KO, and CB2R-KO mice at 1, 2, 3, and 4 DPI. (C) Body condition scores in WT, CB1R-KO, and CB2R-KO mice at 4 DPI. (D) Serum IL-1 β levels in WT, CB1R-KO, and CB2R-KO mice at 4 DPI. (E) Serum TNF- α levels in WT, CB1R-KO, and CB2R-KO mice at 4 DPI. (F) Kaplan-Meier survival curves for WT, CB1R-KO, and CB2R-KO mice over 4 DPI. *Data are presented as mean $\pm$ SEM. For panels (A), (C), (D), and (E), one-way ANOVA was used for statistical analysis. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.

Figure 5. Gut microbiome alterations in CB2R-KO mice during *Salmonella* infection. (A) Alpha diversity of the gut microbiota in CB2R knockout (CB2R-KO) and wild-type (WT) mice at baseline (pre-infection) and 4 days post-infection (dpi) with *Salmonella Typhimurium*. Alpha diversity was assessed using the Shannon diversity index. The Kruskal-Wallis test was performed for significance test. (B–C) Differential abundance analysis of microbial taxa 4 days post-infection. Blue bars indicate taxa enriched in WT; red bars indicate enrichment in CB2R-KO. Circle size represents $-\log_{10}(\text{p-value})$.

821 **Figure 6. Functional microbiome analysis of CB2R-KO vs. WT mice post-infection. (A).** The
822 volcano plot displays differentially abundant metabolic pathways, with red indicating pathways
823 enriched in WT and blue in CB2R-KO. **(B)** Bar plots highlight significantly altered pathways,
824 including downregulation of *Bifidobacterium* shunt activity, L-glutamine, and L-lysine biosynthesis
825 in CB2R-KO mice. Circle size reflects $-\log_{10}(\text{p-value})$.
826




Fig.1.

Figure 1




Fig.2.

Figure 2




Fig.3.

Figure 3




Fig.4.
Figure 4




Fig.5





Fig.6
Figure 6